Insulin Glargine in Type 2 Diabetes

Sanofi

Status and phase: Completed; Phase 4

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Insulin Glargine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00268645

HOE901_5036

Details and patient eligibility

About

The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 Diabetes Mellitus patients,
• Diabetic patients receiving insulin or patients who are insulin-naive and whose glycemic control cannot be sufficiently maintained with single or combined oral antidiabetic agents,
• Patients with HbA1C>8
• Patients able to self-measure its blood glucose levels.

Exclusion criteria

• According to package insert information (Summary of Product Characteristics)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)